Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers
Home › TX › MESQUITE › TOTS N TEENS CLINICS

TOTS N TEENS CLINICS

NPI: 1285942920 · MESQUITE, TX 75150 · Pediatric Sleep Medicine Physician · NPI assigned 09/15/2010

$4.73M
Total Medicaid Paid
229,185
Total Claims
175,650
Beneficiaries
86
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialABO KAYASS, AHMAD (OWNER)
NPI Enumeration Date09/15/2010

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 104 $2K
2019 337 $6K
2020 13,500 $295K
2021 55,669 $1.41M
2022 51,419 $959K
2023 59,656 $947K
2024 48,500 $1.11M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 18,668 15,889 $829K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 21,468 18,107 $709K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 5,335 4,584 $692K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) 5,320 4,746 $311K
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) 5,641 4,727 $273K
90460 Immunization administration through 18 years of age via any route, first or only component 26,694 11,519 $249K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) 3,306 3,016 $209K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) 2,035 1,893 $147K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A 10,553 9,552 $134K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type 7,223 3,380 $112K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) 2,587 2,366 $105K
87428 1,923 1,755 $95K
92552 3,428 3,086 $74K
99381 1,335 1,189 $61K
99383 878 788 $57K
69210 1,541 1,314 $51K
90677 1,189 1,085 $51K
99215 Prolong outpt/office vis 665 608 $47K
96110 Developmental screening, with scoring and documentation, per standardized instrument 5,831 4,295 $45K
95004 Percutaneous tests with allergenic extracts, immediate type reaction 107 107 $43K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 545 505 $35K
99000 3,469 3,066 $33K
99384 461 419 $32K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 2,512 2,316 $30K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 355 345 $29K
90461 14,784 5,731 $29K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) 792 769 $29K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 1,013 955 $24K
90619 340 304 $20K
87807 1,942 1,772 $20K
99382 326 297 $19K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 315 307 $18K
G8510 Screening for depression is documented as negative, a follow-up plan is not required 2,828 1,913 $15K
83655 1,814 1,594 $13K
97802 4,153 3,869 $9K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 841 790 $9K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 743 564 $9K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 349 324 $8K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 378 350 $8K
95810 Polysomnography; sleep staging with 4 or more additional parameters 24 17 $7K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction 371 333 $5K
96161 5,476 4,584 $4K
54450 81 73 $4K
95115 411 150 $3K
81002 814 732 $2K
99050 222 210 $2K
85018 1,286 1,138 $2K
90670 3,015 2,608 $2K
90651 1,118 1,022 $1K
92567 104 102 $1K
84030 492 397 $1K
90680 2,776 2,396 $980.21
90698 3,061 2,643 $967.75
90621 225 207 $879.09
36415 Collection of venous blood by venipuncture 2,584 2,167 $761.60
A7003 Administration set, with small volume nonfiltered pneumatic nebulizer, disposable 320 289 $752.50
90710 1,386 1,198 $735.03
94760 543 464 $488.77
90648 1,108 976 $361.20
90744 2,151 1,941 $306.05
90633 2,307 2,033 $301.05
94010 12 12 $289.68
90696 907 784 $280.00
90707 794 690 $262.53
90716 722 630 $262.52
90715 597 509 $189.48
96380 13 13 $171.82
90686 1,988 1,894 $146.72
90713 120 112 $120.30
90700 1,211 1,065 $108.07
69209 12 12 $77.47
J1100 Injection, dexamethasone sodium phosphate, 1 mg 271 247 $27.76
99173 6,190 5,578 $17.50
96160 13 13 $11.25
90734 514 442 $0.07
S3620 Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) 81 74 $0.03
90688 442 426 $0.01
99441 32 18 $0.00
J7611 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg 31 31 $0.00
90381 17 15 $0.00
96127 120 90 $0.00
90656 194 194 $0.00
A9150 Non-prescription drugs 13 13 $0.00
99072 21,277 16,864 $0.00
J7699 Noc drugs, inhalation solution administered through dme 31 31 $0.00
90380 21 17 $0.00